Neuromodulatory mechanisms of sodium-glucose cotransporter 2 inhibi-tors in treatment of heart failure
10.3969/j.issn.1000-4718.2025.08.024
- VernacularTitle:钠-葡萄糖共转运体2抑制剂治疗心力衰竭的神经调节机制
- Author:
Jiayue ZHONG
1
;
Bo DONG
;
Xiaojing WU
Author Information
1. 深圳大学,广东 深圳 518055
- Publication Type:Journal Article
- Keywords:
sodium-glucose cotransporter;
heart failure;
sympathetic nerve;
neuromodulation
- From:
Chinese Journal of Pathophysiology
2025;41(8):1652-1657
- CountryChina
- Language:Chinese
-
Abstract:
Sodium glucose cotransporter(SGLT)2 inhibitors,initially developed as antihyperglycemic agents,have demonstrated remarkable cardioprotective effects in numerous clinical trials and are now utilized in the treat-ment of heart failure across a range of ejection fractions.SGLT2 is predominantly expressed in the renal proximal tubules,brain,and epicardial adipose tissue within the human body.Research indicates that the protective effects of SGLT2 inhibi-tors in heart failure are linked to their direct modulation of SGLT2 receptors in both the kidneys and epicardial adipose tis-sue.Furthermore,SGLT is also present in the brain,and recent studies have revealed that SGLT2 inhibitors can enhance sympathetic activity in patients with metabolic syndrome,suggesting a potential neuroregulatory role.Given that excessive activation of the sympathetic nervous system can contribute to the onset and progression of heart failure,this paper reviews the neural regulatory mechanisms of SGLT2 inhibitors to provide insights for a deeper understanding of heart failure and to optimize their clinical application.
